IMCC IM Cannabis Corp. IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1792030 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY1.3%
TTM net income YoY-6.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.2%
Net income 3-yr CAGR—
Margins
Gross margin17.7%
Operating margin-21.2%
Net margin-20.7%
FCF margin8.6%
EBITDA margin—
Returns
ROE-1,496.2%
ROA-31.9%
ROIC (approx.)-63.6%
Asset turnover1.54x
Leverage & solvency
Liabilities / assets111.4%
Debt / equity—
Current ratio0.67x
Interest coverage-3.31x
Cash quality & payout
Operating cash flow / net income-0.42x
Accruals ratio-45.2%
Payout ratio—
Capex / revenue0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | 54.73M | 54.03M |
| Cost of revenue | 45.05M | 45.58M |
| Gross profit | 9.69M | 8.45M |
| SG&A expense | 9.52M | 8.02M |
| Operating income | -11.59M | -10.23M |
| Interest expense | 3.50M | 4.77M |
| Pretax income | -11.66M | -12.79M |
| Income tax | 92,000 | -1.02M |
| Net income | -11.32M | -10.59M |
| EPS (basic) | — | -4.51 |
| EPS (diluted) | — | -4.51 |
| Balance sheet | ||
| Cash & equivalents | 2.73M | 863,000 |
| Receivables | 4.32M | 5.42M |
| Inventory | 4.27M | 3.21M |
| Current assets | 22.74M | 23.36M |
| PP&E, netmay include right-of-use assets (IFRS) | 3.71M | 3.73M |
| Goodwill | 1.89M | 6.68M |
| Intangibles | 1.22M | 3.33M |
| Total assets | 31.74M | 39.19M |
| Current liabilities | 34.01M | 34.92M |
| Short-term debt | 14.33M | 15.14M |
| Long-term debt | 936,000 | 466,000 |
| Total debt | 15.27M | 15.61M |
| Total liabilities | 35.35M | 36.04M |
| Shareholders' equity | -3.73M | 5.24M |
| Net debt | 12.54M | 14.75M |
| Shares outstanding | 5.89M | 3.09M |
| Cash flow statement | ||
| Operating cash flow | 4.72M | -1.08M |
| Capital expenditure | 13,000 | 156,000 |
| Free cash flow | 4.70M | -1.23M |
| Investing cash flow | -531,000 | -470,000 |
| Financing cash flow | 1.15M | 3.83M |
| Stock-based compensation | 14,000 | 369,000 |
Free plan shows the latest 2 periods; Pro shows all 7 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.